This Article Full Text Full Text (PDF) Data Supplement Correction (v52,pe30) All Versions of this Article: 51/6/1442    most recent HYPERTENSIONAHA.107.108530v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kuipers, I. Articles by de Boer, R. A. Search for Related Content PubMed PubMed Citation Articles by Kuipers, I. Articles by de Boer, R. A. Related Collections Cardio-renal physiology/pathophysiology Lipids ACE/Angiotension receptors Animal models of human disease Other hypertension Clinical Studies

(Hypertension. 2008;51:1442.)
© 2008 American Heart Association, Inc.

Brief Reviews

Nuclear Hormone Receptors as Regulators of the Renin-Angiotensin-Aldosterone System

Irma Kuipers; Pim van der Harst; Gerjan Navis; Linda van Genne; Fulvio Morello; Wiek H. van Gilst; Dirk J. van Veldhuisen; Rudolf A. de Boer

From the Departments of Cardiology (I.K., P.v.d.H., L.v.G., W.H.v.G., D.J.v.V., R.A.d.B.) and Nephrology (G.N.), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; and the IVth Division of Internal Medicine (F.M.), San Vito Hospital, Torino, Italy.

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
The renin-angiotensin-aldosterone system (RAAS) has been identified as the main system involved in blood pressure regulation, renal hemodynamics, and sodium-volume homeostasis. Furthermore, the RAAS directly affects vascular and cardiac remodeling through proliferative and inflammatory signaling. Pharmacological targeting of the RAAS is a consolidated and evidence-based approach in the treatment of various aspects of cardiovascular disease. An exploding number of recent studies have provided novel insights into nuclear receptor biology in relation to cardiovascular (patho)physiology. In particular, members of the nuclear hormone receptor (NHR) superfamily have been identified as key molecules in various relevant cellular processes. As such, NHRs have been proposed as amenable targets for therapy, and their role in cardiovascular disease is currently explored.

This review focuses on the potential effects of NHRs on the RAAS, summarizing the extensive body of evidence from experimental, animal, and clinical studies, suggesting that NHRs and the RAAS are closely intertwined. We discuss how these findings might translate into the clinical setting and discuss the (older) trials that evaluated NHR agonists in humans. We postulate that therapies targeting NHRs will cause ancillary effects (ie, modulating the RAAS) that need to be considered.

	NHRs and the RAAS

 
NHRs constitute a superfamily of ligand-activated transcription factors involved in multiple cellular functions, acting as monomers, homodimers, or heterodimers (usually with the retinoid X receptors). The NHR superfamily is divided into 6 subfamilies (Table S1, available in the data supplement online at http://hyper.ahajournals.org).¹ Cloning of the NHRs revealed that many of the NHRs share close homology. The fourth, fifth, and sixth . . . [Full Text of this Article]